全文获取类型
收费全文 | 43393篇 |
免费 | 3930篇 |
国内免费 | 111篇 |
专业分类
耳鼻咽喉 | 340篇 |
儿科学 | 1018篇 |
妇产科学 | 967篇 |
基础医学 | 6421篇 |
口腔科学 | 656篇 |
临床医学 | 4342篇 |
内科学 | 8426篇 |
皮肤病学 | 542篇 |
神经病学 | 4062篇 |
特种医学 | 1212篇 |
外国民族医学 | 3篇 |
外科学 | 6236篇 |
综合类 | 1070篇 |
一般理论 | 98篇 |
预防医学 | 4153篇 |
眼科学 | 1321篇 |
药学 | 3489篇 |
中国医学 | 45篇 |
肿瘤学 | 3033篇 |
出版年
2023年 | 257篇 |
2022年 | 328篇 |
2021年 | 937篇 |
2020年 | 582篇 |
2019年 | 940篇 |
2018年 | 971篇 |
2017年 | 730篇 |
2016年 | 815篇 |
2015年 | 1008篇 |
2014年 | 1377篇 |
2013年 | 1981篇 |
2012年 | 2717篇 |
2011年 | 2908篇 |
2010年 | 1624篇 |
2009年 | 1411篇 |
2008年 | 2427篇 |
2007年 | 2542篇 |
2006年 | 2485篇 |
2005年 | 2503篇 |
2004年 | 2465篇 |
2003年 | 2158篇 |
2002年 | 2042篇 |
2001年 | 731篇 |
2000年 | 684篇 |
1999年 | 725篇 |
1998年 | 534篇 |
1997年 | 466篇 |
1996年 | 432篇 |
1995年 | 426篇 |
1994年 | 361篇 |
1993年 | 352篇 |
1992年 | 508篇 |
1991年 | 492篇 |
1990年 | 449篇 |
1989年 | 470篇 |
1988年 | 398篇 |
1987年 | 402篇 |
1986年 | 382篇 |
1985年 | 436篇 |
1984年 | 360篇 |
1983年 | 313篇 |
1982年 | 249篇 |
1981年 | 214篇 |
1980年 | 207篇 |
1979年 | 245篇 |
1978年 | 193篇 |
1977年 | 171篇 |
1974年 | 184篇 |
1973年 | 167篇 |
1972年 | 170篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
James A. Akingbasote Alison J. Foster Ian Wilson Sunil Sarda Huw B. Jones J. Gerry Kenna 《Archives of toxicology》2016,90(4):853-862
Hepatic NADPH-cytochrome P450 oxidoreductase null (HRN?) mice exhibit normal hepatic and extrahepatic biotransformation enzyme activities when compared to wild-type (WT) mice, but express no functional hepatic cytochrome P450 activities. When incubated in vitro with [14C]-diclofenac, liver microsomes from WT mice exhibited extensive biotransformation to oxidative and glucuronide metabolites and covalent binding to proteins was also observed. In contrast, whereas glucuronide conjugates and a quinone-imine metabolite were formed when [14C]-diclofenac was incubated with HRN? mouse liver, only small quantities of P450-derived oxidative metabolites were produced in these samples and covalent binding to proteins was not observed. Livers from vehicle-treated HRN? mice exhibited enhanced lipid accumulation, bile duct proliferation, hepatocellular degeneration and necrosis and inflammatory cell infiltration, which were not present in livers from WT mice. Elevated liver-derived alanine aminotransferase, glutamate dehydrogenase and alkaline phosphatase activities were also observed in plasma from HRN? mice. When treated orally with diclofenac for 7 days, at 30 mg/kg/day, the severities of the abnormal liver histopathology and plasma liver enzyme findings in HRN? mice were reduced markedly. Oral diclofenac administration did not alter the liver histopathology or elevate plasma enzyme activities of WT mice. These findings indicate that HRN? mice are valuable for exploration of the role played by hepatic P450s in drug biotransformation, but poorly suited to investigations of drug-induced liver toxicity. Nevertheless, studies in HRN? mice could provide novel insights into the role played by inflammation in liver injury and may aid the evaluation of new strategies for its treatment. 相似文献
6.
7.
8.
9.
Rohi Shah Nomaan Sheikh Jitendra Mangwani Nicolette Morgan Hamidreza Khairandish 《Journal of Clinical Orthopaedics and Trauma》2021,12(1):138
Demographic projections for hip fragility fractures indicate a rising annual incidence by virtue of a multimorbid, ageing population with more noncommunicable diseases (NCDs). NCDs are characterised by slow progression and long duration ranging from ischaemic cardiovascular disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease to various cancers. Management of this disease burden often involves commencing patients on oral anticoagulants to reduce the risk of thromboembolic events. The use of direct oral anticoagulants (DOACs) in clinical practice has increased due to their rapid onset of action, short half-life and predictable anticoagulant effects, without the need for routine monitoring. Safe and timely surgical intervention relies on reversal of anticoagulants. However, the lack of specific evidence-based guidelines for the perioperative management of patients on DOACs with hip fractures has proved challenging; in particular, the accessibility of DOAC-specific assays, justification of the cost-benefit ratio of targeted reversal agents and indications for neuraxial anaesthesia. This has led to potentially avoidable delays in surgical intervention. Following a literature review of the pharmacokinetic and pharmacodynamics of commonly used DOACs in our region including the role of surrogate markers, we propose a systematic, evidence-based guideline to the perioperative management of hip fractures DOACs. We believe this standardised protocol can be easily replicated between hospitals. We recommend that if patients are deemed suitable for a general anaesthesia, with satisfactory renal function, optimal surgical time should be 24 h following the last ingested dose of DOAC. 相似文献
10.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献